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ABSTRACT: The NOG gene encodes noggin, a secreted
polypeptide that is important for regulating multiple
signaling pathways during human development, particu-
larly in cartilage and bone. The hallmark of NOG-related
syndromes is proximal symphalangism, defined by
abnormal fusion of the proximal interphalangeal joints
of the hands and feet. Many additional features secondary
to NOG mutations are commonly but inconsistently
observed, including a characteristic facies with a hemi-
cylindrical nose, congenital conductive hearing loss due
to stapes fixation, and hyperopia. The variable clinical
presentations led to the designation of five different
autosomal dominant syndromes, all subsequently found
to have resulted from NOG mutations. These include
(1) proximal symphalangism; (2) multiple synostoses
syndrome 1; (3) stapes ankylosis with broad thumbs and
toes; (4) tarsal-carpal coalition syndrome; and (5)
brachydactyly type B2. Herein, we review the phenotypic
features associated with mutations in the NOG gene,
demonstrating the overlapping characteristics of these
syndromes. Due to the variable phenotypic spectrum
within families and among families with the same mutation,
we propose a unifying term, NOG-related symphalangism
spectrum disorder (NOG-SSD), to aid in the clinical
recognition and evaluation of all affected individuals with
these phenotypes. These NOG gene variants are available
in a new locus-specific database (https://NOG.lovd.nl).
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Background
The NOG (MIM] 602991) gene encodes a secreted protein
called noggin that is essential for normal bone and joint
development [Zimmerman et al., 1996]. NOG maps to human
chromosome band 17q22 [Valenzuela et al., 1995] and consists of
a single coding exon of 696 bp, encoding a 232 amino acid protein
that is secreted as a homodimer. Noggin binds and inactivates
bone morphogenetic proteins (BMPs) [Brunet et al., 1998],
specific signaling proteins of the transforming growth factor-b
(TGF-b) superfamily. BMPs function by binding to Type I and
Type II bone morphogenic protein receptors (BMPRs) on the cell
surface and triggering a phosphorylation cascade that eventually
leads to activation of transcription factors [Zakin and De Robertis,
2010]. The 15 known members of the BMP family (BMP1–
BMP15) are responsible for the differentiation of mesenchymal
cells [Hogan, 1996], and thus may also be referred to as growth
differentiation factors (GDFs), comprising another family within
the TGF-b superfamily. BMPs and noggin have been implicated in
regulating multiple processes during embryogenesis, including
establishment of the dorsoventral axis, neural induction and
neurogenesis, and formation of bones and joints in the developing
skeletal system [Brunet et al., 1998; McMahon et al., 1998]. BMPs
are responsible for osteogenic transformation of stem cells,
activation of immature osteoblasts [Cheng et al., 2003], and
induction of apoptosis at joint sites [Zou and Niswander, 1996].
A variety of skeletal dysplasias may result from abnormal signaling
through the BMP pathway (reviewed by [Baldridge et al., 2010]).
When noggin is absent, BMPs are unregulated, and chondrocytes
undergo hyperplasia instead of apoptosis in the developing joint
[Dawson et al., 2006].
Currently, noggin is the only secreted inhibitor of BMPs that has
been associated with abnormal phenotypes in humans. Fusion of
the proximal interphalangeal joints, known as proximal sympha-
langism, is the most widely recognized hallmark feature caused by
NOG mutations. Proximal symphalangism displays minimal
genetic heterogeneity, as mutations in only two other genes,
GDF5 (MIM] 601146) and FGF9 (MIM] 600921), have been
reported in a small number of families (see Diagnostic Relevance,
below). Several additional features have been described that
comprise overlapping clinical syndromes associated with NOG
mutations, including proximal symphalangism (MIM] 185800),
multiple synostoses syndrome 1 (MIM] 186500), tarsal-carpal
coalition syndrome (MIM] 186570), stapes ankylosis with broad
thumbs and toes (MIM] 184460), and brachydactyly type B2
(MIM] 611377). We propose a new term, NOG-SSD (NOG-related
symphalangism spectrum disorder), to encompass these disorders.
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SYM1 is characterized by variable fusion of the proximal
interphalangeal joints and occasionally the metacarpophalangeal
joints in the hands. The third, fourth, and fifth digits are more
frequently affected than the index fingers, and the thumb is almost
always spared. In 1916, Cushing described a family with proximal
symphalangism segregating as an autosomal dominant trait with
complete penetrance [Cushing, 1916]. Affected individuals were
noted to have ‘‘straight fingers,’’ or symphalangism, and an
inability to make a fist, as well as hearing loss, shortened middle
fingers, and straight and/or webbed toes. A family with similar
features with the exception of hearing loss was reported the next
year by Drinkwater [1917]. In 1965, a follow-up report of
Cushing’s family described several members with talonavicular
and calcaneocuboidal coalitions, resulting in a waddling or ‘‘duck-
like’’ gait, in addition to bony fusions in the hands [Strasburger,
1965]. Numerous reports described families presenting with
dominantly inherited symphalangism, hearing loss, and fusion
of the carpals and tarsals [Bloom, 1937; Spoendlin, 1974; Sugiura
and Inagaki, 1981]. Other features identified in affected
individuals include hyperopia, fused cervical vertebrae, abnormal
facies, absent flexion creases of the digits, shortened metacarpals,
distal symphalangism, hypoplasia or aplasia of the distal phalanges
in the hands and feet, and symphalangism in the toes. Premature
ovarian failure was also reported in one Japanese female with
SYM1 [Kosaki et al., 2004].
In 1995, linkage analysis in Cushing’s family identified a locus
for proximal symphalangism on human chromosome band
17q21–q22 [Polymeropoulos et al., 1995], and subsequently,
missense mutations in the NOG gene were reported in this family
and five other families with proximal symphalangism [Gong et al.,
1999]. Mutations causing proximal symphalangism are listed in
Table 1 [Mangino et al., 2002; Takahashi et al., 2001].
Multiple Synostoses Syndrome 1 (SYNS1)
SYNS1 was initially described as an autosomal dominant
disorder characterized by progressive symphalangism and con-
ductive hearing loss secondary to stapes fixation [Gorlin et al.,
1970]. Multiple synostoses syndrome was clinically distinguished
from proximal symphalangism based on the presence of
characteristic facial features and by more severe and widespread
joint involvement, especially in the vertebrae and hips [Maroteaux
et al., 1972]. The joint fusions typically worsened with aging in the
affected individuals [Gaal et al., 1987].
In multiple synostoses syndrome, the facies are characterized
by low frontal hair implantation, a broad, tubular shaped
(hemicylindrical) nose with lack of alar flare, thin vermilion of
the upper lip, short philtrum, and microstomia [Higashi and
Inoue, 1983]. Additional features include multiple joint fusions
in the hands, feet, hips, and cervical vertebrae, brachydactyly,
hypoplastic or absent phalanges in the hands, hypoplastic or
absent nails, shortened metacarpals, subluxation of the radial
heads, pectus carinatum, strabismus, and hyperopia [da-Silva
et al., 1984; Gaal et al., 1987; Konigsmark and Gorlin, 1976].
Although some reports lacked formal audiological test results of
individuals or did not differentiate sensorineural from conductive
hearing loss, reported hearing impairment ranged from mild to
severe [Gaal et al., 1987]. As in proximal symphalangism, the
proximal interphalangeal joints of the ulnar-sided digits are
generally affected first, followed by involvement of the radial-sided
digits, with sparing of the thumbs. Most affected adults are unable
to make a fist. Over time, affected individuals developed fusions of
the cervical vertebrae, hips, and humeroradial joints. The cervical
vertebral fusions began to develop in childhood and eventually led
to significantly limited neck range of motion by adulthood.
Multiple synostoses syndrome has also been described as
WL symphalangism-brachydactyly syndrome [Herrmann, 1974;
Higashi and Inoue, 1983] and facioaudiosymphalangism [Hurvitz
et al., 1985; van den Ende et al., 2005]. Linkage analysis of a family
with multiple synostoses syndrome mapped to the same locus
(17q21–q22) as proximal symphalangism [Krakow et al., 1998],
and mutations in the NOG gene were later described in several
families with multiple synostoses syndrome [Dawson et al., 2006;
Debeer et al., 2005; Emery et al., 2009; Gong et al., 1999; Takahashi
et al., 2001] (Table 1).
Tarsal-Carpal Coalition Syndrome (TCC)
TCC syndrome was described as an autosomal dominant
disorder characterized by fusion of the carpals, tarsals, and
phalanges in addition to shortened first metacarpals, brachydac-
tyly, and humeroradial fusion [Drawbert et al., 1985; Gregersen
and Petersen, 1977]. Conductive hearing loss is not typically
observed in tarsal-carpal coalition syndrome [Dixon et al., 2001].
Beginning at birth, affected members show progressive fusion of
the proximal interphalangeal joints, starting at the fifth digit and
proceeding sequentially to the second digit, with sparing of the
thumb. With age, affected individuals may develop humeroradial
fusion and elbow abnormalities. Other features may include flat
feet, varus or valgus deformities of the heel, fixed pronation or
supination of the forefoot, and low body height. The abnormali-
ties of the ankle and foot can cause significant discomfort and
disability in these affected individuals, often requiring palliative or
surgical intervention. Four different NOG mutations have been
identified in families with TCC [Debeer et al., 2004; Dixon et al.,
2001; Drawbert et al., 1985] (Table 1).
Stapes Ankylosis with Broad Thumbs and Toes (SABTT)
Stapes ankylosis with broad thumbs and toes was described
as an autosomal dominant disorder characterized by bilateral
conductive hearing loss secondary to stapes ankylosis, significant
hyperopia, broad thumbs, and broad first toes [Teunissen and
Cremers, 1990]. In contrast, fewer than 3% of total cases of SYM1
and SYNS1 report hyperopia [Hilhorst-Hofstee et al., 1997].
Fusion of cervical vertebrae, characteristic facies akin to multiple
synostoses syndrome, strabismus, and syndactyly of the toes may
also be observed [Brown et al., 2003]. However, SABTT differs
from SYM1 and SYNS1 by the presence of hyperopia and the lack
of fusions in the carpals or tarsals.
Nonsense mutations within the NOG gene were reported in two
families with stapes ankylosis with broad thumbs and toes, one of
which was previously described by Milunsky [Brown et al., 2002,
2003; Milunsky et al., 1999]. These two families had similar
phenotypes, with the exception of tall stature (490% percentile)
and lack of childbearing by affected females in one family. Several
additional NOG mutations associated with SABTT were sub-
sequently reported [Hirshoren et al., 2008; Thomeer et al., 2011;
Weekamp et al., 2005] (Table 1). Notably, in contrast to the
missense mutations in NOG typically associated with SYM1,
SYNS1, and TCC, six of the eight known mutations to cause
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Table 1. DNA Variants in the NOG Gene and Predicted Functional Consequences
Nucleotide changea Protein Predicted and/or demonstrated effect on protein Syndrome previous publications
c.58delC p.Leu20Cysfs42 Frameshift SYNS1 Takahashi et al., 2001
Truncated protein with 60 amino acids
Missing cysteine-rich C-terminal domain
c.103C4G p.Pro35Ala Missense BDB2 Lehmann et al., 2007
Decreased affinity for BMP; prevents interaction with BMP type I receptors
c.103C4T p.Pro35Ser Missense SABTT Hirshoren et al., 2008
Conformational change; prevents interaction with BMP type I receptors BDB2 Lehmann et al., 2007
SYM1 Mangino et al., 2002
c.104C4G p.Pro35Arg Missense SYM1 Gong et al., 1999
Conformational change; prevents interaction with BMP type I receptors TCC Dixon et al., 2001
c.106G4C p.Ala36Pro Missense BDB2 Lehmann et al., 2007
Conformational change; prevents interaction with BMP type I receptors
c.110C4G p.Pro37Arg Missense TCC Debeer et al., 2004
Destruction of beta-sheet motif and conformational change; prevents
interaction with BMP type I receptors
c.[124C4G; 149C4G] p.[Pro42Ala;
Pro50Arg]
Double missense mutation SYNS1 Debeer et al., 2004
c. 125C4G p.Pro42Arg Missense SYNS1 Oxley et al., 2008
c.129_130dup p.Val44Glyfs19 Frameshift SABTT Weekamp et al., 2005
Truncated protein with 61 amino acids
No functional noggin protein synthesized
c.142G4A p.Glu48Lys Missense BDB2 Lehmann et al., 2007
Conformational change; inhibits interaction with BMP type II receptors SYM1 Kosaki et al., 2004
c.252dup p.Glu85Argfs97 Frameshift SABTT Brown et al., 2002
Truncated protein with 180 amino acids
Missing cysteine-rich C-terminal domain
c.304del p.Ala102Argfs22 Frameshift SABTT Thomeer et al., 2011
c.328C4T p.Gln110 Nonsense SABTT Brown et al., 2002
Truncated protein with 109 amino acids
Missing cysteine-rich C-terminal domain
c.386T4A p.Leu129 Nonsense SYM1 Takahashi et al., 2001
Truncated protein with 128 amino acids
Missing cysteine-rich C-terminal domain
c. 391C4T p.Gln131 Nonsense SABTT Thomeer et al., 2011
Truncated protein with 130 amino acids
c.499C4G p.Arg167Gly Missense BDB2 Lehmann et al., 2007
Conformational change; prevents interaction with BMP type II receptors
c.551G4A p.Cys184Tyr Missense SYM1 Takahashi et al., 2001
c.559C4T p.Pro187Ser Missense BDB2 Lehmann et al., 2007
Destabilizes binding of noggin homodimers; secretion of monomeric forms
c.561del p.Glu188Argfs76 Frameshift SABTT Weekamp et al., 2005
Elongated protein with 262 amino acids.
Missing second finger structure and likely conformational change
c.565G4T p.Gly189Cys Missense SYM1 Gong et al., 1999
Secreted mostly in monomer form
Significantly decreased levels of dimeric noggin
c.568A4G p.Met190Val Missense SYNS1 Oxley et al., 2008
c.608T4C p.Leu203Pro Missense SABTT Weekamp et al., 2005
Conformational change in second finger structure
c.611G4T p.Arg204Leu Missense TCC Dixon et al., 2001
c.614G4A p.Trp205 Nonsense SYNS1 Dawson et al., 2006
Truncated protein with 204 amino acids
c.615G4C p.Trp205Cys Missense SYNS1 van den Ende et al.,
2005
SYM1 Emery et al., 2009
c.649T4G p.Trp217Gly Missense SYNS1 Gong et al., 1999
Loss of noggin secretion; unable to bind BMPs





Double missense mutation SYM1 Gong et al., 1999
c.665A4G p.Tyr222Cys Missense SYM1 Gong et al., 1999
TCC Dixon et al., 2001
c.668C4T p.Pro223Leu Missense SYM1 Gong et al., 1999
Secreted in dimer form
Decreased levels of disulfide-linked dimeric noggin
c.696C4G p.Cys232Trp Missense SYNS1 Rudnik-Schöneborn
Disrupts cysteine-rich C-terminal domain et al., 2010
SYNS1, multiple synostoses syndrome 1; BMP, bone morphogenetic protein; BDB2, brachydactyly type B2; SABTT, stapes ankylosis, broad thumbs and toes; SYM1, proximal
symphalangism; TCC, tarsal-carpal coalition syndrome.
aNucleotide and amino acid alterations are displayed in Human Genome Variation Society preferred format (www.hgvs.org/mutnomen) [den Dunnen and Antonarakis, 2000].
Nucleotide numbering is based on GenBank reference sequence NM_005450.4. All listed variants occur in exon 1, the single coding exon of NOG.
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SABTT are inactivating mutations, suggesting that haploinsuffi-
ciency of NOG may specifically lead to the SABTT phenotype.
Brachydactyly Type B2 (BDB2)
The brachydactylies are a group of autosomal dominant
disorders characterized by shortened digits in the hands or feet
due to abnormal development of the phalanges or metacarpals/
metatarsals [Bell, 1951]. Brachydactylies are classified into
subtypes A to E based on the degree and pattern of skeletal
involvement [Fitch, 1979]. For example, in type A brachydactylies,
only the middle phalanges are abnormal. Brachydactyly type B
classically involves hypoplasia or aplasia of the middle and/or
terminal phalanges and is the only subtype in which the terminal
phalanges are abnormal. Brachydactyly type B2 was characterized
by hypoplasia or aplasia of the distal and/or middle phalanges
in combination with proximal symphalangism, carpal synostosis,
syndactyly, and rarely, distal symphalangism [Lehmann et al.,
2007]. Proximal symphalangism is commonly noted when the
distal phalanges are present. Similar to SYM1, the fourth and
fifth digits tend to be affected more frequently than the second or
third digits in brachydactyly Type B2.
Truncating mutations in the tyrosine kinase-like orphan
receptor 2 gene (ROR2; MIM] 602337) are responsible for
brachydactyly type B1 (BDB1; MIM] 113000) [Oldridge et al.,
2000]. BDB2 was described in a family in which every affected
member exhibited absent or hypoplastic middle and/or terminal
phalanges, consistent with brachydactyly type B, but no mutations
in ROR2 were found [Brunet et al., 1998]. Among six families with
different NOG mutations causing BDB2 (Table 1), hearing loss
was not reported, although it is unclear whether formal
audiological testing was performed [Lehmann et al., 2007].
NOG Mutation Database
A locus-specific mutation database has been created for the
NOG gene using the LOVD platform (https://NOG.lovd.nl).
Variants
There are few reported polymorphisms in the NOG gene
(Table 2). The completed DNA sequence of human chromosome
17 demonstrated five variants in exon 1: a predicted frameshift,
c.19delC; two nonsynonomous base substitutions, p.Asp60Asn
and p.Trp150Gly, and two synonomous base substitutions [Zody
et al., 2006]. As these DNA sequence variants were discovered in
presumably asymptomatic individuals, no phenotypic informa-
tion is available.
Several genetic association studies have investigated NOG as a
candidate susceptibility gene for various disorders. Significant
associations between single nucleotide polymorphisms (SNPs)
mapping to human chromosome band 17q22–17q23 have been
demonstrated for nonsyndromic cleft lip and palate [Mangold
et al., 2010] and adult human height [Gudbjartsson et al., 2008].
No significant associations were detected between polymorphisms
in the NOG gene and the incidence of osteoporosis phenotypes
[Moffett et al., 2009] or the degree of volumetric bone mineral
density [Yerges et al., 2009].
Biological Relevance
In mice, homozygous Noggin null mutations led to a recessive
lethal phenotype at birth with multiple abnormalities involving
the neural tube, limbs, vertebrae, and tail [Brunet et al., 1998;
McMahon et al., 1998]. Although null mice had normal induction
of neural tissue, they subsequently displayed failure of neural tube
closure, reduced amount of posterior neural tissue, and failure of
ventral development in the posterior neural tube. Additionally,
somite differentiation was deficient due to reduced induction and
impaired survival of sclerotomal and myotomal derivatives in the
trunk. Due to excess cartilage production, the skeleton was
affected by widespread joint fusion involving the axial skeleton
and limbs [Brunet et al., 1998]. It was also noted that GDF-5
expression was significantly decreased or absent in the affected
joint cavities.
The phenotype of heterozygous Noggin null mice varied with
the background strain, suggesting that modifier genes play a role
Table 2. Polymorphisms in the NOG Gene
Region Nucleotide changea Affected codon Reference number Allele frequencyb Previous publications
50 UTR c.520G.A p. 5 NA 0.98/0.02 Moffet et al., 2009
50 UTR c.385C4A p. 5 rs117249328 ND Zody et al., 2006
50 UTR c.73G4A p. 5 NA 0.81/0.19 Moffet et al., 2009
Exon 1 c.19delC p.Leu7 rs34711886 ND NCBI SNPdb
Exon 1 c.178G4A p.Asp60Asn rs117165670 ND Zody et al., 2006
Exon 1 c.448T4G p.Trp150Gly rs118090182 ND Zody et al., 2006
Exon 1 c.561C4T p. 5 rs116863344 ND Zody et al., 2006
Exon 1 c.582G4A p. 5 rs76347008 0.789/0.211 Zody et al., 2006
30 UTR c.80A4C p. 5 rs1442829 ND NCBI SNPdb
30 UTR c.110T4C p. 5 rs1236187 ND NCBI SNPdb
30 UTR c.130_135del p. 5 rs71671792 ND Zody et al., 2006
30 UTR c.130_135del p. 5 rs67555616 ND Zody et al., 2006
30 UTR c.130_135del p. 5 rs71888945 ND Zody et al., 2006
30 UTR c.136_137del p. 5 rs71139919 ND Zody et al., 2006
30 UTR c.153A4G p. 5 rs74256715 ND NCBI SNPdb
30 UTR c.303A4C p. 5 rs1348322 ND NCBI SNPdb
30 UTR c.567G4C p. 5 rs116716909 ND Zody et al., 2006
Nucleotide and amino acid alterations are displayed in Human Genome Variation Society preferred format (www.hgvs.org/mutnomen) [den Dunnen and Antonarakis, 2000]
where ‘‘’’ indicates nucleotides upstream of the initiation codon, indicates nucleotides downstream of the termination codon, and 11 corresponds to the A of the ATG
initiation codon; UTR, untranslated region; ND, not determined; NA, not available.
aNucleotide numbering is based on GenBank reference sequence NM_005450.4.
bAllele frequency from NCBI Single Nucleotide Polymorphism Database [Sherry et al., 2001] or cited reference.
880 HUMAN MUTATION, Vol. 32, No. 8, 877–886, 2011
[Hwang and Wu, 2008]. Nog1/ embryos were reported as normal
in one study [Brunet et al., 1998], whereas Nog1/ mice on a
congenic C57BL/6J background demonstrated conductive hearing
loss secondary to impaired mobility of the stapes [Hwang and
Wu, 2008]. In contrast, Nog1/ mice on a mixed C57BL/6J/FVB
background had normal hearing. Observations from mouse
models as well as variability seen across the human spectrum
may suggest epistatic modifiers for the NOG gene.
In vitro studies have examined the synthesis, secretion, and
BMP binding activity of mutant noggin proteins (p.Gly189Cys,
p.Pro223Leu, and p.Tryp217Gly) [Marcelino et al., 2001].
Although mutant noggin was transcribed and translated similar
to wild-type noggin, the mutant polypeptides were less efficient at
forming disulfide linkage bonds. Mutant proteins expressing
p.Gly189Cys and p.Pro223Leu were secreted as monomers or
dimers in lower amounts compared to wild type, and were able to
interact with GDF-5. In contrast, the p.Tryp217Gly mutant
protein failed to be secreted at all and was unable to interact
with GDF-5. Interestingly, GDF-5 facilitated the formation of
dimers in all three mutant proteins. The same three mutant
proteins retained their ability to function as secreted dimers in
Xenopus laevis embryos.
The C-terminal region of noggin contains a cysteine-knot motif
of nine cysteine residues important for dimerization and disulfide-
bond formation (between residues 155 and 192, 178 and 228, 184
and 230, and 207 and 215) [Groppe et al., 2002]. Truncations or
alterations of the C-terminal region are therefore likely to alter
protein function [Groppe et al., 2003]. Six of eight mutations
associated with SABTT are nonsense mutations, which may result
in truncation of the C-terminal domain or haploinsufficiency
through nonsense-mediated decay (Table 1).
The known NOG mutations associated with abnormal pheno-
types tend to cluster in areas that affect noggin’s ability to bind
to the Type I and Type II receptor pockets on BMPs (Table 1).
The P35 amino acid appears to be crucial for binding to the Type I
receptor pocket on BMPs via a hydrophobic interaction; thus,
substitutions at this site may decrease affinity or induce steric
hindrance [Lehmann et al., 2007]. Interestingly, three different
missense mutations involving this residue have been reported
(Table 1) (p.Pro35Ala in BDB2; p.Pro35Ser in SABTT, BDB2,
and SYM1; and p.Pro35Arg in SYM1 and TCC). It has been
suggested that when containing mutations associated with
BDB2, noggin may either retain most of its function in binding
BMPs/GDFs or act through a different mechanism [Lehmann
et al., 2007]. For example, the BDB2 mutation p.Pro187Ser is
thought to affect the dimerization domain of noggin and inhibit
its ability to form a homodimer [Lehmann et al., 2007].
One study used computer simulation to calculate the free-
binding energy between noggin and GDF5, comparing the
loss of energy with a variety of noggin mutants in comparison
to wild-type noggin [Lehmann et al., 2007]. The highest loss of
free-binding energy was observed for p.Pro35Arg, with inter-
mediate reduction in free energy observed for p.Pro35Ala and
p.Pro35Ser, and negligible decreases were noted for p.Ala36Pro,
p.Glu48Lys, and p. Arg167Gly. However, in chick limb buds,
the p.Glu48Lys and p.Pro35Arg mutants were unable to inhibit
chondrogenesis, indicating significantly decreased affinity for
BMPs [Groppe et al., 2003].
BMPs and GDF5 bind to BMPR1 and BMPR2, which are
specific transmembrane serine/threonine kinases located on the
cell surface [Gilboa et al., 2000]. After ligand binding, the BMPRs
form heterodimers, and BMPR2 phosphorylates BMPR1. If the
BMP/GDF binds to a preformed heterodimer, the phosphorylated
BMPR1 subsequently activates SMAD proteins by phosphoryla-
tion [Nohe et al., 2002]. The SMAD proteins enter the nucleus to
regulate transcription of genes related to bone formation [von
Bubnoff and Cho, 2001]. Thus, the level of activation of SMAD
proteins is a means to assay NOG activity. Upregulation of BMPs
and GDFs produces phenotypes similar to those associated with
downregulation of NOG.
Clinical Relevance
Despite the descriptions of several different syndromes to date
and the wide spectrum of phenotypes arising secondary to NOG
mutations, there are common overlapping features. These
anomalies most commonly involve abnormal bone and joint
formation, from the ears to the toes, but may also involve
development of facial structures and vision. We propose that a
more broadly inclusive clinical diagnostic term, NOG-related
Symphalangism Spectrum Disorder (NOG-SSD), may offer
significant clinical and research utility. Although recognizing
NOG mutations as the common molecular etiology, this term
also incorporates the hallmark feature of proximal symphalan-
gism, whereas noting the variable spectrum of associated findings.
The reported clinical findings in NOG-SSD are summarized in
Table 3.
Table 3. Physical Features Characteristic of NOG-
Symphalangism Spectrum Disorder
Site Features
Face Broadened, hemicylindrical nose with bulbous tip and lack of alar flare
Shortened philtrum







Ears Conductive hearing loss, unilateral or bilateral
Neck Limited neck flexion, extension, and lateral bending
Hands Proximal symphalangism, inability to flex proximal interphalangeal joints of
second through fifth digits and/or inability to make a fist (medial digits
more commonly affected)
Shortening or absence of distal portions of fingers (medial-sided digits
affected preferentially)
Broad and/or short thumbs
Limited wrist flexion and extension
Absent creases on flexor and/or extensor surfaces of interphalangeal joints
Absent or shortened fingernails
Clinodactyly
Syndactyly
Elbows Limited flexion and extension of the elbow
Limited pronation and supination of the forearm
Chest Pectus carinatum
Pectus excavatum
Hips Limited range of motion




Absent or shortened toenails
Fixed valgus or varus deformity of heel
Fixed pronation or supination of forefoot
Limited inversion or eversion
Pes planus
Shortened or absence of distal portions of toes
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Joint and Bone Anomalies
Most affected individuals with NOG-SSD express some degree of
joint or bone deformity, although the severity of the deformities
demonstrates both significant inter- and intrafamilial variability.
Both hands and feet may display syndactyly, shortening or complete
absence of the distal portions of the phalanges, shortening or complete
absence of fingernails, and abnormally broad first digits (‘‘hammer’’
thumbs and toes). Joint ankyloses in the cervical vertebrae, elbows,
and/or hips are commonly observed. Thorough visual inspection of
the hands and feet, in addition to range-of-motion testing in the neck,
elbows, hands, hips, and feet, is essential in these patients.
The hands display the greatest amount of variation in NOG-
SSD. Narrowing and eventual fusion of the proximal interpha-
langeal (PIP) joints occurs most frequently, with the ulnar-sided
digits being affected more frequently than the radial-sided digits.
In milder cases of NOG-SSD, the proximal interphalangeal joints
are spared. The severity of PIP involvement tends to diminish
toward the radial side of the hand (i.e., the fourth and fifth digits
are much more likely to be affected than the second or third
digits) [Strasburger, 1965]. Fusion of the PIP joints in the hands
leads to decreased ability to flex the fingers and make a fist, as well
as abnormalities in the pattern of interphalangeal creases (loss of
creases or additional creases) on the flexor and/or extensor sides of
the digits. However, these anomalies are not traditionally
described as debilitating.
Fusion between any of the carpal bones is a rather common
occurrence in NOG-SSD. Other possible findings include
shortened or elongated metacarpals, and broadened metacarpals
or thumbs. The distal and/or middle phalanges may be
hypoplastic or completely absent, leading to shortened digits. In
rare cases, there may be distal interphalangeal joint fusion, but
these joints as well as the metacarpophalangeal joints are not
typically affected.
In the feet, there may be fusion of the proximal or distal
interphalangeal joints and broad phalanges, especially the hallux.
Unlike the fingers, the toes do not demonstrate a pattern of joint
involvement. The distal and/or middle phalanges of the feet may
be hypoplastic or absent, resulting in shorter toes. The metatarsals
may occasionally become fused with the tarsals or phalanges.
Positioning abnormalities such as pes planus, fixed varus or valgus
angulation of the heel, and fixed pronation or supination of the
forefoot are also observed, which may result in painful callosities
on the lateral portions of the feet [Drawbert et al., 1985]. Fusion
between any of the tarsal bones is extremely common and
debilitating, causing pain and difficulty with ambulation, some-
times described as a ‘‘duck-like’’ gait.
Limited range of motion due to joint ankylosis may involve the
spine, elbows, and hips, and, rarely, the shoulders. Joint ankylosis
tends to worsen over time and may not be noticeable until later in
life. For example, one affected adult lacked the mobility to tie a
necktie or to fold his legs in a pretzel or Indian-style fashion but
otherwise had no limitations of daily activities. In the spine,
fusion may develop between two or more adjacent vertebrae. The
majority of fusions occur in the cervical vertebrae, leading over
time to difficulties with neck flexion and extension. Other findings
may include degeneration of the vertebrae, broadening of the
spinal processes and laminae, narrowing of the intervertebral
space, schmorl nodes, and spinal canal stenosis. The head of the
radius is frequently deformed, resulting in subluxation of the
radial head or humeroradial synostosis.
Radiological imaging may be helpful in the diagnosis and
treatment of individuals with NOG-SSD (Table 4). The types of
defects range from altered shapes of bones, shortened or absent
bones, fusion between bones, and narrowed or absent joint spaces.
Advanced bone age may also be noticed in children. Individuals
with NOG-SSD may exhibit premature fusion of phalangeal
growth plates, leading to short phalanges. In normal individuals,
phalangeal growth plates fuse by age 25, and therefore imaging at a
younger age is necessary to detect premature fusion.
Joint fusions in the hands, elbows, or spine rarely warrant
surgical intervention, and attempts to create interphalangeal joints
have been largely unsuccessful [Smith and Lipke, 1979]. Tarsal
coalition may result in severe, disabling pain that can be treated by
nonsteroidal anti-inflammatory medications, ankle-stabilizing
orthotics, or casting. Surgical options include excision of the
coalitions and arthodesis of the joints [Thometz, 2000]. Specific
success rates of standard procedures such as osteotomy and
arthroplasty in patients affected by NOG-SSD have not been
described.
Facial Features
Multiple families with NOG-SSD demonstrated characteristic
facial features in multiple generations. The most prominent
feature is a broad, hemicylindrical or tubular nose with a bulbous
tip, hypoplastic nasal alae, and short philtrum [Higashi and Inoue,
1983]. A posteriorly sloping forehead, prominent supraorbital
ridges, clefting of the nasal tip, malar flattening, synophrys, and a
cleft chin may also be evident (Fig. 1). Other facial features may
include a thin vermilion of the upper lip and upslanting palpebral
fissures.
Otologic and Audiologic Findings
Congenital conductive hearing loss due to stapes ankylosis is a
well-defined feature in NOG-SSD. The conductive hearing loss
presents in childhood, and onset may be difficult to determine in
patients born before 2000, when newborn hearing screening
became widely adopted [Vesell, 1960]. Moderate conductive
hearing loss may be stable for years, but progression of stapes
ankylosis is commonly described in families with SYM1 [Baschek,
Table 4. Radiological Findings Characteristic of NOG-
Symphalangism Spectrum Disorder
Site Features
Head Deformities of stapes
Narrowing of oval window
Hands Symphalangism of the proximal interphalangeal joints (medial digits
affected preferentially)
Hypoplastic or absent distal and/or middle phalanges (medial digits affected
preferentially)
Narrowed interphalangeal joint spaces
Broadened and/or shortened thumb
Broadened, shortened, or elongated metacarpals
Carpal fusions
Elbow Subluxation of the radial head
Humeroradial fusions
Spine Vertebral fusions (most commonly in cervical vertebrae)
Narrowed intervertebral spaces
Broadening of spinal processes and laminae
Degenerative changes
Feet Fusion of the proximal or distal interphalangeal joints
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1978; Cremers et al., 1985; Gorlin et al., 1970; Spoendlin, 1974;
Stenger and Gloede, 1972]. The penetrance of hearing loss in
NOG-SSD may range from low (33–50%) [Declau et al., 2001;
Takahashi et al., 2001] to complete [Ensink et al., 1999].
Audiological evaluation typically demonstrates absent stapedial
reflexes and absent otoacoustic emissions unilaterally or bilaterally.
Typical of conductive hearing loss, speech discrimination is usually
normal while the speech reception threshold is increased. The
severity of hearing impairment can range from 20 to 80 dB,
although most affected individuals have at least moderate hearing
loss (440 dB). Audiometric evaluation is imperative for children
possibly affected by NOG-SSD.
Surgical exploration of the middle ear is necessary to evaluate
the mobility of the ossicular chain by palpation. Fixation of the
short process of the incus, elongation of the long process of the
incus, and fixation of the malleoincudal joint or other ossicular
articulations may also be observed [Ensink et al., 1999; Stephan,
2006; Thomeer et al., 2011; Weekamp et al., 2005]. Previous
histological reports on resected stapes have noted an abnormal
bony bridge between the crura and footplate, local bony fusion of
the stapes footplate with thickened bone in the oval window niche,
and abnormal ossification in the vestibular area of the footplate
with calcification of the annular ligament [Declau et al., 2001].
Temporal bone CT may reveal narrowing of the oval window
and deformities of the stapes [Brown et al., 2003]. However,
high-resolution CT and MRI scans of the temporal bone are
often normal in patients with NOG-SSD [Declau et al., 2001;
Thomeer et al., 2011]. As stapes ankylosis is a clinical diagnosis,
imaging may be most useful to exclude other causes of conductive
hearing loss.
Most patients with pure conductive hearing loss will be success-
ful hearing aid users, but many patients may opt for surgery to
improve their hearing by restoring function of the ossicular chain.
Stapedotomy or stapedectomy followed by placement of a piston is
the most commonly performed procedure. In the short-term after
surgery, most patients show immediate improvement in hearing and
a reduction in the air-bone gap, sometimes with complete closure.
Other patients have no change in hearing or, in rare instances,
worsening of the hearing loss. Long-term follow-up often shows
recurrence of hearing loss, with need for reexploration and revision
surgery after two years [Ensink et al., 1999; Weekamp et al., 2005].
In postoperative patients with recurrence of hearing loss,
temporal bone CT may reveal incudomallear ankylosis, piston
extrusion, or regrowth of bone over the stapes footplate [Brown
et al., 2003]. Patients may also develop an additional sensorineural
component to the hearing loss [Brown et al., 2003]. The
suboptimal long-term surgical results likely reflect the inability
of a mutant noggin protein to inhibit bone regrowth. Although
caution must be used when comparing surgical results from years
ago to modern approaches, overall results of surgery are thought
to be poorer in patients with congenital stapes fixation than in
patients with nonsyndromic otosclerosis [Massey et al., 2006].
Ocular Findings
Hyperopia is a prominent feature in NOG-SSD, specifically in
patients without proximal symphalangism or other widespread
joint fusions. The hyperopia presents in early childhood, and
corrective lenses are often required at an early age. Eyeglasses and
contact lenses are effective treatments. The severity of the
hyperopia may possibly require up to 114 diopters correction
or more. Strabismus occurs quite frequently and can lead to
amblyopia if untreated. Ophthalmologic evaluation is warranted
in all children being evaluated for NOG-SSD.
General
Height, weight, intelligence, and life expectancy are generally
normal. Tall stature has been reported in individuals with SABTS
[Brown et al., 2002] and SYNS1 [Rudnik-Schoneborn et al., 2010],
particularly in childhood [Oxley et al., 2008]. The disability in
these patients mainly arises from difficulties with hearing, vision,
and/or painful ambulation. Although limited range of motion and
impaired flexibility of various joints may be evident on physical
examination, these features may not significantly limit activities of
daily living. In general, conservative treatments are recommended
to improve function and reduce pain in patients with NOG-SSD.
Figure 1. A: Frontal photograph of a 67-year-old male diagnosed
with stapes ankylosis, broad thumbs and toes, demonstrating
posteriorly sloping forehead, prominent supraorbital ridges, broad
hemicylindrical nose with bulbous tip, short columella, and nasal tip
cleft, short philtrum, malar flattening, synophrys, and prominent chin
with midline cleft. B: Lateral view. [Color figures can be viewed in the
online issue, which is available at www.wiley.com/humanmutation.]
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Diagnostic Relevance
The constellation of joint fusions, stapes ankylosis, and
abnormalities of the hands and feet (Table 2) is overall highly
predictive of a NOG mutation, but there is some evidence of
genetic heterogeneity. Mutations in the GDF5 gene have been
reported in patients with clinical features of multiple synostoses
syndrome 2 [Akarsu et al., 1999; Dawson et al., 2006] and
proximal symphalangism [Seemann et al., 2005; Wang et al., 2006;
Yang et al., 2008]. Multiple synostoses syndrome 3 was described
in a family segregrating a mutation in the fibroblast growth factor
9 gene (FGF9; MIM] 600921) [Wu et al., 2009]. It has been
suggested that the FGF and BMP signaling pathways may have
overlapping roles in specifying the developing joints [Baldridge
et al., 2010]. Interestingly, mutations in GDF5 and FGF9 are not
associated with hearing loss, suggesting that the bony abnormal-
ities spare the ossicles.
Stapes ankylosis is a feature of multiple syndromes, such as
osteogenesis imperfecta [Pedersen, 1984], multiple epiphyseal
dysplasia [Beighton et al., 1978], and X-linked stapes ankylosis
with perilymphatic gusher [de Kok et al., 1995]. Isolated stapes
ankylosis is more commonly due to nonsyndromic otosclerosis,
which has a prevalence of 0.3 to 0.4% in Caucasians [Declau et al.,
2001]. However, many individuals who are thought to have
nonsyndromic otosclerosis may actually have stapes ankylosis as
part of a genetic syndrome, and, in addition to a thorough family
history, genetic testing may be useful in discriminating between
the two [Emery et al., 2009].
Future Prospects and Nomenclature
Recommendations
Of the several secreted proteins now known to modulate BMP
activity, noggin was one of the first recognized and most studied
antagonists of BMP function [Marcelino et al., 2001; Smith and
Harland, 1992]. Noggin has been shown to interact with BMP-7
by binding and masking both the Type-I receptor and Type-II
receptor sites located on the BMP [Groppe et al., 2003]. Missense
mutations may lead to misfolding, decreased stability, decreased
affinity to BMPs, or reduced/undetectable secretion of noggin
[Groppe et al., 2003; Lehmann et al., 2007; Marcelino et al., 2001].
It is currently unknown whether truncating mutations cause the
same decrease in noggin secretion as the missense mutations,
although it is expected there would be a decreased affinity for
BMPs. It has been suggested that the more severe pathology
in SYNS1 results from upregulation of GDF5 due to lack of
inhibition [Dawson et al., 2006]. Therapeutic approaches may
include treatments to upregulate NOG or to downregulate BMP/
GDF activity.
For many genetic disorders with a common molecular etiology,
a diverse set of syndromes were initially characterized on pheno-
typic grounds. Incorporating molecular genetic data into the
nomenclature without losing an extensive body of clinical infor-
mation often presents a challenge [Biesecker, 1998]. Remarkably,
the need to simplify classification of syndromes associated with
proximal symphalangism was noted over 30 years ago [Nixon,
1978]. We propose a unifying term, NOG-related Symphalangism
Spectrum Disorder (NOG-SSD), to aid in the clinical diagnosis
and evaluation of affected individuals. Proximal symphalangism is
the hallmark feature most consistently noted, although it may vary
in extent and distribution. The spectrum varies from milder
phenotypes (SABTT, BDB2) to moderate (TCC) to severe (SYM1,
SYNS1). Within a family, certain features are more consistently
observed across generations than others. Furthermore, the same
mutation (such as p.Pro35Ser) has been described in patients
diagnosed with different clinical disorders (Table 1). Use of one
common diagnostic term may help simplify the establishment and
dissemination of clinical diagnostic criteria and enable the
development of more focused and robust counseling, evaluation,
and educational tools for patients.
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